Osaic Holdings’s Lantern Pharma LTRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$917 Hold
220
﹤0.01% 7513
2026
Q1
$301 Buy
220
+5
+2% +$14 ﹤0.01% 7512
2025
Q4
$651 Hold
215
﹤0.01% 7393
2025
Q3
$935 Hold
215
﹤0.01% 7380
2025
Q2
$679 Buy
215
+115
+115% +$388 ﹤0.01% 7280
2025
Q1
$354 Buy
+100
New +$415 ﹤0.01% 7072
2024
Q2
Sell
-410
Closed -$3.61K 7530
2024
Q1
$3.61K Buy
410
+210
+105% +$1.12K ﹤0.01% 6231
2023
Q4
$856 Hold
200
﹤0.01% 6800
2023
Q3
$682 Hold
200
﹤0.01% 6926
2023
Q2
$1.13K Buy
+200
New +$1.03K ﹤0.01% 6848
2023
Q1
Sell
-864
Closed -$5K 7546
2022
Q4
$5K Hold
864
﹤0.01% 6285
2022
Q3
$4K Sell
864
-2,496
-74% -$13.4K ﹤0.01% 6489
2022
Q2
$19K Buy
3,360
+285
+9% +$1.7K ﹤0.01% 5653
2022
Q1
$22K Sell
3,075
-2,256
-42% -$15.1K ﹤0.01% 5628
2021
Q4
$43K Buy
5,331
+2,561
+92% +$23.4K ﹤0.01% 5253
2021
Q3
$31K Buy
2,770
+1,770
+177% +$22.9K ﹤0.01% 5461
2021
Q2
$15K Sell
1,000
-300
-23% -$4.63K ﹤0.01% 5828
2021
Q1
$24K Buy
+1,300
New +$22.8K ﹤0.01% 5363

Other funds holding LTRN

Osaic Holdings's LTRN Position: Q2 2026 in Review

Osaic Holdings held its Lantern Pharma (LTRN) position steady in Q2 2026 at 220 shares worth $917. The position accounts for ﹤0.01% of the portfolio, ranked #7513.

Osaic Holdings first reported a position in LTRN in Q1 2021 and has held it in 18 quarters since. The position peaked at $43K in Q4 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Osaic Holdings held 220 shares of Lantern Pharma worth $917 as of Q2 2026.
  • Osaic Holdings left its Lantern Pharma share count unchanged in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7513 holding.
  • Osaic Holdings first reported a position in Lantern Pharma in Q1 2021 and has held it in 18 quarters since.
  • Osaic Holdings's Lantern Pharma position peaked at $43K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.